Oral polio vaccine response in the MAL-ED birth cohort study: Considerations for polio eradication strategies.
Antibodies, Neutralizing
/ blood
Cohort Studies
Disease Eradication
/ methods
Feces
/ virology
Female
Global Health
Humans
Immunization Programs
Immunization Schedule
Infant
Male
Neutralization Tests
Poliomyelitis
/ immunology
Poliovirus
/ immunology
Poliovirus Vaccine, Inactivated
/ administration & dosage
Poliovirus Vaccine, Oral
/ administration & dosage
Serogroup
Vaccination Coverage
/ methods
Enteropathogen infection
Home environment
Oral polio vaccination
Poliomyelitis
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
07 01 2019
07 01 2019
Historique:
received:
02
02
2018
revised:
15
05
2018
accepted:
17
05
2018
pubmed:
18
11
2018
medline:
14
8
2019
entrez:
17
11
2018
Statut:
ppublish
Résumé
Immunization programs have leveraged decades of research to maximize oral polio vaccine (OPV) response. Moving toward global poliovirus eradication, the WHO recommended phased OPV-to-IPV replacement on schedules in 2012. Using the MAL-ED prospective birth cohort data, we evaluated the influence of early life exposures impacting OPV immunization by measuring OPV response for serotypes 1 and 3. Polio neutralizing antibody assays were conducted at 7 and 15 months of age for serotypes 1 and 3. Analyses were conducted on children receiving ≥3 OPV doses (n = 1449). History of vaccination, feeding patterns, physical growth, home environment, diarrhea, enteropathogen detection, and gut inflammation were examined as risk factors for non-response [Log Serotype 1 seroconversion was significantly higher than serotype 3 (96.6% vs. 89.6%, 15 months). Model results indicate serotypes 1 and 3 failure was minimized following four and six OPV doses, respectively; however, enteropathogen detection and poor socioeconomic conditions attenuated response in both serotypes. At three months of age, bacterial detection in stool reduced serotype 1 and 3 Log Under real-world conditions, improved vaccination coverage and socio-environmental conditions, and reducing early life bacterial exposures are key to improving OPV response and should inform polio eradication strategies.
Sections du résumé
BACKGROUND
Immunization programs have leveraged decades of research to maximize oral polio vaccine (OPV) response. Moving toward global poliovirus eradication, the WHO recommended phased OPV-to-IPV replacement on schedules in 2012. Using the MAL-ED prospective birth cohort data, we evaluated the influence of early life exposures impacting OPV immunization by measuring OPV response for serotypes 1 and 3.
METHODS
Polio neutralizing antibody assays were conducted at 7 and 15 months of age for serotypes 1 and 3. Analyses were conducted on children receiving ≥3 OPV doses (n = 1449). History of vaccination, feeding patterns, physical growth, home environment, diarrhea, enteropathogen detection, and gut inflammation were examined as risk factors for non-response [Log
FINDINGS
Serotype 1 seroconversion was significantly higher than serotype 3 (96.6% vs. 89.6%, 15 months). Model results indicate serotypes 1 and 3 failure was minimized following four and six OPV doses, respectively; however, enteropathogen detection and poor socioeconomic conditions attenuated response in both serotypes. At three months of age, bacterial detection in stool reduced serotype 1 and 3 Log
INTERPRETATION
Under real-world conditions, improved vaccination coverage and socio-environmental conditions, and reducing early life bacterial exposures are key to improving OPV response and should inform polio eradication strategies.
Identifiants
pubmed: 30442479
pii: S0264-410X(18)30746-1
doi: 10.1016/j.vaccine.2018.05.080
pmc: PMC6325791
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Poliovirus Vaccine, Inactivated
0
Poliovirus Vaccine, Oral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
352-365Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Lancet Infect Dis. 2015 Aug;15(8):889-97
pubmed: 26093979
Pediatr Infect Dis J. 1995 Feb;14(2):100-6
pubmed: 7746690
Indian Pediatr. 1990 Sep;27(9):911-4
pubmed: 2286433
Risk Anal. 2013 Apr;33(4):544-605
pubmed: 22804479
Vaccine. 2014 Jan 16;32(4):478-82
pubmed: 24300591
Indian J Pediatr. 1993 Mar-Apr;60(2):275-81
pubmed: 8244504
Br Med J. 1976 Apr 3;1(6013):812
pubmed: 1260345
Pediatr Infect Dis J. 2004 Dec;23(12):1130-6
pubmed: 15626951
J Infect Dis. 1990 Dec;162(6):1291-7
pubmed: 2172403
N Engl J Med. 1961 May 25;264:1071-8
pubmed: 13761025
EBioMedicine. 2015 Sep 25;2(11):1759-66
pubmed: 26870801
J Infect Dis. 1997 Feb;175 Suppl 1:S258-63
pubmed: 9203726
J Trop Pediatr. 1989 Feb;35(1):19-23
pubmed: 2709485
Vaccine. 2017 Jan 11;35(3):443-451
pubmed: 27998640
Trans R Soc Trop Med Hyg. 2007 Nov;101(11):1124-30
pubmed: 17765275
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S248-54
pubmed: 25305294
J Infect Dis. 1993 Aug;168(2):452-4
pubmed: 8335983
EBioMedicine. 2017 Apr;18:109-117
pubmed: 28396264
Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S413-8
pubmed: 6740083
Pediatrics. 1964 Jul;34:4-13
pubmed: 14181984
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S220-4
pubmed: 25305290
Am J Epidemiol. 1972 Oct;96(4):263-9
pubmed: 4342327
MMWR Morb Mortal Wkly Rep. 2014 Nov 14;63(45):1031-3
pubmed: 25393222
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S207-12
pubmed: 25305288
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S261-72
pubmed: 25305296
J Sch Psychol. 2017 Oct;64:109-127
pubmed: 28735604
Popul Health Metr. 2014 Mar 21;12(1):8
pubmed: 24656134
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S239-47
pubmed: 25305293
Vaccine. 2016 May 11;34(22):2519-26
pubmed: 27085172
J Infect Dis. 2010 May 15;201(10):1535-43
pubmed: 20367459
PLoS One. 2017 Mar 9;12(3):e0172134
pubmed: 28278161
Rev Infect Dis. 1991 Sep-Oct;13(5):926-39
pubmed: 1660184
JAMA. 2007 Oct 24;298(16):1900-10
pubmed: 17954541
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S193-206
pubmed: 25305287
Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):815-6
pubmed: 9923532
Am J Dis Child. 1985 Oct;139(10):977-80
pubmed: 2994463
Lancet. 2008 Mar 8;371(9615):828-37
pubmed: 18328930
PLoS Pathog. 2012;8(4):e1002599
pubmed: 22532797
Rev Saude Publica. 1985 Feb;19(1):51-7
pubmed: 3001923
Lancet. 1988 Feb 27;1(8583):429-33
pubmed: 2893864
J Immunol. 1999 Apr 15;162(8):5011-8
pubmed: 10202050
Lancet Glob Health. 2015 Sep;3(9):e564-75
pubmed: 26202075
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S225-32
pubmed: 25305291
Am J Trop Med Hyg. 2017 Feb 8;96(2):465-472
pubmed: 27994110
J Infect Dis. 1991 Jan;163(1):1-6
pubmed: 1845806
J Infect Dis. 1995 May;171(5):1097-106
pubmed: 7751683
J Infect Dis. 2014 Nov 1;210 Suppl 1:S434-8
pubmed: 25316865
Bull World Health Organ. 1974;51(4):333-47
pubmed: 4142936
Popul Health Metr. 2012 Dec 13;10(1):24
pubmed: 23237098
Am J Trop Med Hyg. 2017 Jul;97(1):281-290
pubmed: 28719336
Bull World Health Organ. 1976;54(1):115-7
pubmed: 1087587
Am J Dis Child. 1966 Jan;111(1):27-30
pubmed: 5900282
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S273-9
pubmed: 25305297
Pediatr Infect Dis J. 1996 Mar;15(3):204-9
pubmed: 8852907